Dr Lal Path Labs' Om Manchanda Speaks On Q4 Performance & FY24 Margin Outlook | CNBC-TV18

Dr Lal Path Labs' Om Manchanda Speaks On Q4 Performance & FY24 Margin Outlook | CNBC-TV18Подробнее

Dr Lal Path Labs' Om Manchanda Speaks On Q4 Performance & FY24 Margin Outlook | CNBC-TV18

Dr Lal Path Labs Under Pressure After Nomura Downgrades Stock To 'Neutral' | CNBC TV18Подробнее

Dr Lal Path Labs Under Pressure After Nomura Downgrades Stock To 'Neutral' | CNBC TV18

Dr Om Manchanda On Dr Lal PathLabs' Weak Q3 Earnings & Outlook | Bazaar Corporate Radar | CNBC-TV18Подробнее

Dr Om Manchanda On Dr Lal PathLabs' Weak Q3 Earnings & Outlook | Bazaar Corporate Radar | CNBC-TV18

Will Be Looking At Some Inorganic Growth Opportunities In The Southern Market: Dr Lal PathLabsПодробнее

Will Be Looking At Some Inorganic Growth Opportunities In The Southern Market: Dr Lal PathLabs

Aspiration Is To Grow In Double Digit With Margin At 26% In FY25: Dr Lal Pathlabs | CNBC TV18Подробнее

Aspiration Is To Grow In Double Digit With Margin At 26% In FY25: Dr Lal Pathlabs | CNBC TV18

Dr Lal Path Labs' Om Manchanda Exclusive On The Changing Landscape Of Diagnostics | The Medicine BoxПодробнее

Dr Lal Path Labs' Om Manchanda Exclusive On The Changing Landscape Of Diagnostics | The Medicine Box

Dr Lal Pathlabs: Q1, Margins, Expansion Plans & Capex | Dr. Om Manchanda Explains | Business NewsПодробнее

Dr Lal Pathlabs: Q1, Margins, Expansion Plans & Capex | Dr. Om Manchanda Explains | Business News

Dr Lal Path Labs' Om Manchanda Speaks On Rising Competition In Diagnostics | Bazaar Open ExchangeПодробнее

Dr Lal Path Labs' Om Manchanda Speaks On Rising Competition In Diagnostics | Bazaar Open Exchange

Dr Lal PathLabs' Om Manchanda On Margins | BQ PrimeПодробнее

Dr Lal PathLabs' Om Manchanda On Margins | BQ Prime

Price Increase Is One Of The Reasons For The Margin Expansion: Dr Lal Pathlabs | CNBC TV18Подробнее

Price Increase Is One Of The Reasons For The Margin Expansion: Dr Lal Pathlabs | CNBC TV18

Thursday Thought Leaders |In conversation with Om Manchanda, MD, Dr. Lal's Pathlabs | Episode - 25Подробнее

Thursday Thought Leaders |In conversation with Om Manchanda, MD, Dr. Lal's Pathlabs | Episode - 25

Insight Edge: Dr Lal Pathlabs Buzzing In Trade After Reports Weak Set Of Q4 Numbers | CNBC-TV18Подробнее

Insight Edge: Dr Lal Pathlabs Buzzing In Trade After Reports Weak Set Of Q4 Numbers | CNBC-TV18

New Entrants Have Led To Heavy Discounting In The Industry: Dr Lal PathLabs' Om ManchandaПодробнее

New Entrants Have Led To Heavy Discounting In The Industry: Dr Lal PathLabs' Om Manchanda

Dr Lal Path Labs' Om Manchanda on Q4 results, "Vol growth is certain, western India benefitted"Подробнее

Dr Lal Path Labs' Om Manchanda on Q4 results, 'Vol growth is certain, western India benefitted'

'Demand & Supply Landscape Of Diagnostic Industry Changing', Says Om Manchanda | Halftime ReportПодробнее

'Demand & Supply Landscape Of Diagnostic Industry Changing', Says Om Manchanda | Halftime Report

Q4 Review | How Dr. Lal Pathlabs Plans To Improve FinancialsПодробнее

Q4 Review | How Dr. Lal Pathlabs Plans To Improve Financials

Q4 Results: Dr Lal Pathlabs' MD On Earnings & FY23 GoalsПодробнее

Q4 Results: Dr Lal Pathlabs' MD On Earnings & FY23 Goals

Diagnostics Will Continue To Remain The Mainstay Within Healthcare: Dr Lal Path Labs | CNBC TV18Подробнее

Diagnostics Will Continue To Remain The Mainstay Within Healthcare: Dr Lal Path Labs | CNBC TV18

NPSC Snippets | Dr. Om Manchanda, Managing Director of Dr. Lal PathLabs Ltd.Подробнее

NPSC Snippets | Dr. Om Manchanda, Managing Director of Dr. Lal PathLabs Ltd.

Dr Lal Path Labs, Fortis Healthcare & Apollo; Know All About The Biz Strategy Of Healthcare GiantsПодробнее

Dr Lal Path Labs, Fortis Healthcare & Apollo; Know All About The Biz Strategy Of Healthcare Giants